Compare BBD & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBD | WST |
|---|---|---|
| Founded | 1943 | 1923 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3B | 23.9B |
| IPO Year | 2002 | 2004 |
| Metric | BBD | WST |
|---|---|---|
| Price | $3.58 | $346.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $325.86 |
| AVG Volume (30 Days) | ★ 28.3M | 313.9K |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | ★ 4.82% | 0.30% |
| EPS Growth | N/A | ★ 1.49 |
| EPS | N/A | ★ 4.07 |
| Revenue | N/A | ★ $2,886,900,000.00 |
| Revenue This Year | $70.86 | $6.76 |
| Revenue Next Year | $8.33 | $6.22 |
| P/E Ratio | ★ $9.20 | $82.86 |
| Revenue Growth | N/A | ★ 1.95 |
| 52 Week Low | $2.98 | $223.83 |
| 52 Week High | $4.30 | $386.00 |
| Indicator | BBD | WST |
|---|---|---|
| Relative Strength Index (RSI) | 63.66 | 49.95 |
| Support Level | $3.32 | $323.60 |
| Resistance Level | $3.58 | $359.48 |
| Average True Range (ATR) | 0.10 | 7.05 |
| MACD | 0.05 | -0.64 |
| Stochastic Oscillator | 92.50 | 46.01 |
Banco Bradesco is Brazil's second-largest private bank, with about 10%-15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation, a private nonprofit institution focused on education. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.